Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025. Immutep Limited has released promising initial safety data for ...
Given encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026 including presentation of data at a major medical conference SYDNEY, ...
Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg The substantial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback